Ionis Pharmaceuticals, Inc. (LON:0JDI)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 6.82B +38.2% |
| Revenue (ttm) | 658.80M -7.4% |
| Net Income | -425.97M |
| EPS | -2.61 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 640 |
| Open | 55.40 |
| Previous Close | 55.99 |
| Day's Range | 55.01 - 56.75 |
| 52-Week Range | 40.38 - 86.74 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial numbers in USD Financial StatementsNews
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
Ionis Pharmaceuticals price target raised to $76 from $72 at JPMorgan
JPMorgan raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $76 from $72 and keeps an Overweight rating on the shares. The firm updated the company’s model after meeting…
Ionis Pharmaceuticals price target raised to $93 from $90 at BofA
BofA raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $93 from $90 and keeps a Buy rating on the shares. The firm continues to see a favorable risk/reward…
Ionis Pharmaceuticals price target lowered to $115 from $125 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $115 from $125 and keeps a Buy rating on the shares. The firm views the company’s Q2 report…
Ionis Pharmaceuticals price target raised to $69 from $66 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $66 and keeps a Neutral rating on the shares after its better than expected Q2 results.
Ionis Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 and H1 revenues grew significantly year-over-year, driven by strong launches of TRYNGOLZA and DAWNZERA. TRYNGOLZA's sHTG launch is progressing well, with expanding payer coverage and robust demand, while DAWNZERA continues to gain share in HAE prophylaxis.
Ionis Pharmaceuticals Earnings release: Q2 2026
Ionis Pharmaceuticals released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Ionis Pharmaceuticals Slides: Q2 2026
Ionis Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Ionis Pharmaceuticals Quarterly report: Q2 2026
Ionis Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 29, 2026.
Ionis Pharmaceuticals announces chief scientific officer Bennett to retire
Ionis Pharmaceuticals (IONS) announced that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027. Dr. Bennett will serve as a strategic cons...
Ionis Pharmaceuticals reports Q2 EPS (69c), consensus (88c)
Reports Q2 revenue $268M, consensus $190.09M. “With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis to people…
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective Fe...
Ionis reports second quarter 2026 financial results and highlights progress on key programs
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2026. “Wit...
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage b...
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS
SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biote...
Ionis Pharmaceuticals price target lowered to $89 from $106 at Guggenheim
Guggenheim lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $89 from $106 and keeps a Buy rating on the shares. The firm is revising some of its estimates…
Wolfe cuts Ionis Pharma to Peer Perform after disappointing trial data
Wolfe Research downgraded Ionis Pharmaceuticals (IONS) to Peer Perform from Outperform. Two trial disappointments – TTR and tau – nullified most of the firm’s prior bull thesis, while its remaining…
Ionis Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Ionis Pharmaceuticals (IONS) to Peer Perform from Outperform.
Ionis to hold second quarter 2026 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second qua...
Ionis says Biogen presents Phase 2 CELIA data at AAIC
Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting t...
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranersen, an investigation...
Alnylam price target raised to $485 from $470 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Alnylam (ALNY) to $485 from $470 and keeps a Buy rating on the shares after AstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) recently…
Ionis Pharmaceuticals price target lowered to $85 from $100 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $85 from $100 and keeps an Outperform rating on the shares. The company has an…
Ionis Pharmaceuticals doses first participant in Phase 1-2 ASCEND study
Ionis Pharmaceuticals (IONS) announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet syndrom...
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-...